Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Genes (Basel) ; 15(5)2024 05 08.
Article in English | MEDLINE | ID: mdl-38790223

ABSTRACT

Rett Syndrome (RTT) is a severe neurodevelopmental disorder predominately diagnosed in females and primarily caused by pathogenic variants in the X-linked gene Methyl-CpG Binding Protein 2 (MECP2). Most often, the disease causing the MECP2 allele resides on the paternal X chromosome while a healthy copy is maintained on the maternal X chromosome with inactivation (XCI), resulting in mosaic expression of one allele in each cell. Preferential inactivation of the paternal X chromosome is theorized to result in reduced disease severity; however, establishing such a correlation is complicated by known MECP2 genotype effects and an age-dependent increase in severity. To mitigate these confounding factors, we developed an age- and genotype-normalized measure of RTT severity by modeling longitudinal data collected in the US Rett Syndrome Natural History Study. This model accurately reflected individual increase in severity with age and preserved group-level genotype specific differences in severity, allowing for the creation of a normalized clinical severity score. Applying this normalized score to a RTT XCI dataset revealed that XCI influence on disease severity depends on MECP2 genotype with a correlation between XCI and severity observed only in individuals with MECP2 variants associated with increased clinical severity. This normalized measure of RTT severity provides the opportunity for future discovery of additional factors contributing to disease severity that may be masked by age and genotype effects.


Subject(s)
Methyl-CpG-Binding Protein 2 , Rett Syndrome , Severity of Illness Index , X Chromosome Inactivation , Rett Syndrome/genetics , Rett Syndrome/pathology , X Chromosome Inactivation/genetics , Humans , Methyl-CpG-Binding Protein 2/genetics , Female , Child , Chromosomes, Human, X/genetics , Genotype , Child, Preschool , Adolescent , Adult , Male , Alleles , Young Adult
2.
PLoS One ; 17(10): e0266861, 2022.
Article in English | MEDLINE | ID: mdl-36223387

ABSTRACT

FOXG1 Syndrome (FS) is a devastating neurodevelopmental disorder that is caused by a heterozygous loss-of-function (LOF) mutation of the FOXG1 gene, which encodes a transcriptional regulator important for telencephalic brain development. People with FS have marked developmental delays, impaired ambulation, movement disorders, seizures, and behavior abnormalities including autistic features. Current therapeutic approaches are entirely symptomatic, however the ability to rescue phenotypes in mouse models of other genetic neurodevelopmental disorders such as Rett syndrome, Angelman syndrome, and Phelan-McDermid syndrome by postnatal expression of gene products has led to hope that similar approaches could help modify the disease course in other neurodevelopmental disorders such as FS. While FoxG1 protein function plays a critical role in embryonic brain development, the ongoing adult expression of FoxG1 and behavioral phenotypes that present when FoxG1 function is removed postnatally provides support for opportunity for improvement with postnatal treatment. Here we generated a new mouse allele of Foxg1 that disrupts protein expression and characterized the behavioral and structural brain phenotypes in heterozygous mutant animals. These mutant animals display changes in locomotor behavior, gait, anxiety, social interaction, aggression, and learning and memory compared to littermate controls. Additionally, they have structural brain abnormalities reminiscent of people with FS. This information provides a framework for future studies to evaluate the potential for post-natal expression of FoxG1 to modify the disease course in this severe neurodevelopmental disorder.


Subject(s)
Behavior, Animal , Brain , Forkhead Transcription Factors , Nerve Tissue Proteins , Rett Syndrome , Animals , Brain/anatomy & histology , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Heterozygote , Mice , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Rett Syndrome/genetics
3.
Genes Brain Behav ; 21(1): e12739, 2022 01.
Article in English | MEDLINE | ID: mdl-33942492

ABSTRACT

Rett syndrome is a neurodevelopmental disorder caused predominantly by loss-of-function mutations in MECP2, encoding transcriptional modulator methyl-CpG-binding protein 2 (MeCP2). Although no disease-modifying therapies exist at this time, some proposed therapeutic strategies aim to supplement the mutant allele with a wild-type allele producing typical levels of functional MeCP2, such as gene therapy. Because MECP2 is a dosage-sensitive gene, with both loss and gain of function causing disease, these approaches must achieve a narrow therapeutic window to be both safe and effective. While MeCP2 supplementation rescues RTT-like phenotypes in mouse models, the tolerable threshold of MeCP2 is not clear, particularly for partial loss-of-function mutations. We assessed the safety of genetically supplementing full-length human MeCP2 in the context of the R294X allele, a common partial loss-of-function mutation retaining DNA-binding capacity. We assessed the potential for adverse effects from MeCP2 supplementation of a partial loss-of-function mutant and the potential for dominant negative interactions between mutant and full-length MeCP2. In male hemizygous R294X mice, MeCP2 supplementation rescued RTT-like behavioral phenotypes and did not elicit behavioral evidence of excess MeCP2. In female heterozygous R294X mice, RTT-specific phenotypes were similarly rescued. However, MeCP2 supplementation led to evidence of excess MeCP2 activity in a motor coordination assay, suggesting that the underlying motor circuitry is particularly sensitive to MeCP2 dosage in females. These results show that genetic supplementation of full-length MeCP2 is safe in males and largely so females. However, careful consideration of risk for adverse motor effects may be warranted for girls and women with RTT.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/genetics , Genetic Therapy/methods , Rett Syndrome/therapy , Animals , Basic Helix-Loop-Helix Transcription Factors/metabolism , Female , Genetic Therapy/adverse effects , Humans , Loss of Function Mutation , Male , Mice , Mice, Inbred C57BL , Rett Syndrome/genetics
4.
Hum Mol Genet ; 29(15): 2461-2470, 2020 08 29.
Article in English | MEDLINE | ID: mdl-32469049

ABSTRACT

Rett syndrome (RTT) is a neurodevelopmental disorder primarily caused by mutations in Methyl-CpG-binding Protein 2 (MECP2). More than 35% of affected individuals have nonsense mutations in MECP2. For these individuals, nonsense suppression has been suggested as a possible therapeutic approach. To assess the viability of this strategy, we created and characterized a mouse model with the common p.R294X mutation introduced into the endogenous Mecp2 locus (Mecp2R294X). Mecp2R294X mice exhibit phenotypic abnormalities similar to those seen in complete null mouse models; however, these occur at a later time point consistent with the reduced phenotypic severity seen in affected individuals containing this specific mutation. The delayed onset of severe phenotypes is likely due to the presence of truncated MeCP2 in Mecp2R294X mice. Supplying the MECP2 transgene in Mecp2R294X mice rescued phenotypic abnormalities including early death and demonstrated that the presence of truncated MeCP2 in these mice does not interfere with wild-type MeCP2. In vitro treatment of a cell line derived from Mecp2R294X mice with the nonsense suppression agent G418 resulted in full-length MeCP2 protein production, demonstrating feasibility of this therapeutic approach. Intraperitoneal administration of G418 in Mecp2R294X mice was sufficient to elicit full-length MeCP2 protein expression in peripheral tissues. Finally, intracranial ventricular injection of G418 in Mecp2R294X mice induced expression of full-length MeCP2 protein in the mouse brain. These experiments demonstrate that translational read-through drugs are able to suppress the Mecp2 p.R294X mutation in vivo and provide a proof of concept for future preclinical studies of nonsense suppression agents in RTT.


Subject(s)
Brain/metabolism , Gentamicins/pharmacology , Methyl-CpG-Binding Protein 2/genetics , Rett Syndrome/genetics , Animals , Brain/drug effects , Brain/pathology , Disease Models, Animal , Humans , Methyl-CpG-Binding Protein 2/antagonists & inhibitors , Mice , Mutation/genetics , Neurodevelopmental Disorders/drug therapy , Neurodevelopmental Disorders/genetics , Neurodevelopmental Disorders/pathology , Phenotype , Rett Syndrome/drug therapy , Rett Syndrome/pathology
5.
Anal Chem ; 88(22): 10775-10784, 2016 11 15.
Article in English | MEDLINE | ID: mdl-27732780

ABSTRACT

The cars we drive, the homes we live in, the restaurants we visit, and the laboratories and offices we work in are all a part of the modern human habitat. Remarkably, little is known about the diversity of chemicals present in these environments and to what degree molecules from our bodies influence the built environment that surrounds us and vice versa. We therefore set out to visualize the chemical diversity of five built human habitats together with their occupants, to provide a snapshot of the various molecules to which humans are exposed on a daily basis. The molecular inventory was obtained through untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of samples from each human habitat and from the people that occupy those habitats. Mapping MS-derived data onto 3D models of the environments showed that frequently touched surfaces, such as handles (e.g., door, bicycle), resemble the molecular fingerprint of the human skin more closely than other surfaces that are less frequently in direct contact with humans (e.g., wall, bicycle frame). Approximately 50% of the MS/MS spectra detected were shared between people and the environment. Personal care products, plasticizers, cleaning supplies, food, food additives, and even medications that were found to be a part of the human habitat. The annotations indicate that significant transfer of chemicals takes place between us and our built environment. The workflows applied here will lay the foundation for future studies of molecular distributions in medical, forensic, architectural, space exploration, and environmental applications.


Subject(s)
Ecosystem , Mass Spectrometry , Organic Chemicals/analysis , Organic Chemicals/chemistry , Chromatography, Liquid , Humans , Ions/analysis , Tandem Mass Spectrometry
6.
Hum Mol Genet ; 24(9): 2662-72, 2015 May 01.
Article in English | MEDLINE | ID: mdl-25634563

ABSTRACT

Rett syndrome (RTT) is a severe neurodevelopmental disorder that is usually caused by mutations in Methyl-CpG-binding Protein 2 (MECP2). Four of the eight common disease causing mutations in MECP2 are nonsense mutations and are responsible for over 35% of all cases of RTT. A strategy to overcome disease-causing nonsense mutations is treatment with nonsense mutation suppressing drugs that allow expression of full-length proteins from mutated genes with premature in-frame stop codons. To determine if this strategy is useful in RTT, we characterized a new mouse model containing a knock-in nonsense mutation (p.R255X) in the Mecp2 locus (Mecp2(R255X)). To determine whether the truncated gene product acts as a dominant negative allele and if RTT-like phenotypes could be rescued by expression of wild-type protein, we genetically introduced an extra copy of MECP2 via an MECP2 transgene. The addition of MECP2 transgene to Mecp2(R255X) mice abolished the phenotypic abnormalities and resulted in near complete rescue. Expression of MECP2 transgene Mecp2(R255X) allele also rescued mTORC1 signaling abnormalities discovered in mice with loss of function and overexpression of Mecp2. Finally, we treated Mecp2(R255X) embryonic fibroblasts with the nonsense mutation suppressing drug gentamicin and we were able to induce expression of full-length MeCP2 from the mutant p.R255X allele. These data provide proof of concept that the p.R255X mutation of MECP2 is amenable to the nonsense suppression therapeutic strategy and provide guidelines for the extent of rescue that can be expected by re-expressing MeCP2 protein.


Subject(s)
Alleles , Genetic Association Studies , Methyl-CpG-Binding Protein 2/genetics , Mutation , Phenotype , Amino Acid Substitution , Animals , Behavior, Animal , Disease Models, Animal , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression , Gentamicins/pharmacology , Mechanistic Target of Rapamycin Complex 1 , Methyl-CpG-Binding Protein 2/metabolism , Mice , Mice, Transgenic , Multiprotein Complexes/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rett Syndrome/diagnosis , Rett Syndrome/genetics , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Transgenes
SELECTION OF CITATIONS
SEARCH DETAIL
...